Clinical Trial Update: Dupilumab in Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for dupilumab in chronic spontaneous urticaria and recurrent angioedema completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioedema
• Spontaneous Urticaria

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Chronic Spontaneous Urticaria, Recurrent Angioedema | Phase 2 | Status: COMPLETED